Coronavirus company news summary – Print Parts delivers 3D-printed NP swabs to support Covid-19 testing – Vivera Pharmaceuticals announces Covid-19 diagnostic solution

10 September 2020 (Last Updated September 10th, 2020 09:36)

Chembio Diagnostics, a point-of-care diagnostic company, has submitted an application for Emergency Use Authorisation (EUA) to the US Food and Drug Administration (FDA) for its new rapid antibody test system, DPP SARS-CoV-2 IgM/IgG. This test system detects antibodies to the Spike Receptor Binding Domain in the blood that the body generates in response to a Covid-19 infection.

Print Parts, a US-based additive manufacturing service, has provided over one million nasopharyngeal (NP) swabs for use in NYC Covid-19 test kits. To manufacture these swabs, Print Parts opened a medical manufacturing lab in Manhattan, in collaboration with NYC Health + Hospitals (H+H), the New York City Economic Development Corporation (NYCEDC), Albert Einstein College of Medicine in the Bronx, and Collab, a Brooklyn-based fabrication lab.

Vivera Pharmaceuticals has announced the launch of a partnership with OmeCare, a CLIA-certified global clinical laboratory provider. The Vivera Pharmaceuticals + OmeCare rapid RT-PCR specimen collection kits provide results on for Covid-19 in less than 48 hours.